MindRank backs Phase 3 oral GLP-1 programme with $52m Series B funding
MindRank AI Ltd. has completed a $52 million Series B financing to advance its artificial intelligence-led drug research platform and a clinical pipeline headed by MDR-001, an oral small-molecule glucagon-like peptide-1 receptor agonist already in Phase 3 development in China. The Hangzhou-based biotechnology company said the financing was led by a group of institutional and